注意欠陥多動性障害(ADHD)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0800
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:178
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder – Pipeline Review, H1 2020, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 11, 12, 13, 5 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Attention Deficit Hyperactivity Disorder (ADHD) – Overview
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Development
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment
Attention Deficit Hyperactivity Disorder (ADHD) – Companies Involved in Therapeutics Development
Attention Deficit Hyperactivity Disorder (ADHD) – Drug Profiles
Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Altus Formulation Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Attentive Therapeutics Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Avekshan LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Boston Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cennerv Pharma (S) Pte Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DD Therapeutics LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Co, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by EncepHeal Therapeutics Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Kashiv BioSciences LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Limoxifen BV, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mind Medicine Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Oryzon Genomics SA, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Holdings Co Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by RespireRx Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Seropeutics LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shenox Pharmaceuticals LLC, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shionogi & Co Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Suven Life Sciences Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taho Pharmaceuticals Ltd, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Terran Biosciences Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vallon Pharmaceuticals Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Yuyu Pharma Inc, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2020 (Contd..3), H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2020 (Contd..4), H1 2020
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H1 2020

【掲載企業】

4P-Pharma SAS
AgoneX Biopharmaceuticals Inc
Altus Formulation Inc
Amarantus Bioscience Holdings Inc
Arbor Pharmaceuticals LLC
Attentive Therapeutics Inc
Avekshan LLC
BCWorld Pharm Co Ltd
Boston Pharmaceuticals Inc
Cennerv Pharma (S) Pte Ltd
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Curemark LLC
DD Therapeutics LLC
DURECT Corp
Eli Lilly and Co
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Highland Therapeutics Inc
INVENT Pharmaceuticals Inc
Kashiv BioSciences LLC
KemPharm Inc
Limoxifen BV
Mind Medicine Inc
NLS Pharma Group
Noven Pharmaceuticals Inc
Oryzon Genomics SA
Otsuka Holdings Co Ltd
Otsuka Pharmaceutical Co Ltd
P2D Inc
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Seropeutics LLC
Shenox Pharmaceuticals LLC
Shionogi & Co Ltd
SK Biopharmaceuticals Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Taho Pharmaceuticals Ltd
Terran Biosciences Inc
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Yuyu Pharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[注意欠陥多動性障害(ADHD)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆